^
    Back
    Association details:
    Biomarker:BRCA2 mutation + TP53 mutation
    Cancer:Prostate Cancer
    Drug:Rubraca (rucaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GU 2021
    Title:

    Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).

    Published date:
    02/08/2021
    Excerpt:
    Results from TRITON2 showed antitumor activity for rucaparib in patients with BRCA+ mCRPC associated with or without co-occurring alterations in TP53.
    DOI:
    10.1200/JCO.2021.39.6_suppl.80
    Trial ID:
    TRITON2